← Back to headlines
Eli Lilly Announces Positive Phase 3 Results for Obesity Drug Retatrutide
Eli Lilly (LLY) has reported positive Phase 3 clinical trial results for its investigational obesity treatment, Retatrutide, marking a significant development in the pharmaceutical company's pipeline.
23 May, 12:01 — 23 May, 12:01
Sources
Showing 1 of 1 sources
Related Stories
Finland Adjusts African Swine Fever Containment Measures Amid Outbreak Response
33m ago
Croatia Launches Mosquito Control Operations After West Nile Virus Cases
1h ago
Novartis Halts Autoimmune Cell Therapy Trials After Patient Deaths
2h ago
Spain Records Over 5,000 Heat-Related Deaths During Unprecedented Summer
3h ago